Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. - Wikidata - awgldk - TriplyDB

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.

http://www.wikidata.org/entity/Q36993507

about

Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis.The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis.Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers.MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b.The heritage of glatiramer acetate and its use in multiple sclerosis

P2860

Q30869048-3CB19939-ACDD-49BB-986A-726AA8D7749E Q34090086-03D99866-2477-4CB3-802B-DAAFFD0B9B34 Q35959784-DD02F0C9-F394-472F-BB5E-59475540F5EB Q36211674-06EE0F84-1D54-4609-9B8A-5BF8820BA45A Q37003127-7014F63A-0E4F-4A9A-932A-5EB61F41156C Q38152977-338EF48A-C715-4DB8-9EAB-D2F722576F71 Q38449394-F86649D1-E31E-4016-80A8-18732F54972A Q39037892-AE900B18-5EF1-454F-92B8-CBBB40A432DB Q39544816-7C626941-A341-488D-993D-5133A1A8A2B5 Q56804781-F12040DB-B286-4868-B08C-F10B8959F80A

P2860

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.

http://www.wikidata.org/entity/Q36993507

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.

@en

type

label

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.

@en

prefLabel

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.

@en

P1433

Q36993507-0931495A-1CF1-4685-9151-EC1E9DB1F5B6

P1476

Q36993507-BCB1B0B7-0B4C-4515-91F3-5CEADFE500BE

P2093

Q36993507-2402B761-ED4B-4C38-B40D-F7218BE88B9A

Q36993507-5F0B9E35-348F-44B3-A259-5B188D01438E

Q36993507-ADDCD51E-8D7E-4246-BB16-9F970AC6C958

P2860

Q36993507-18B62896-373C-42F0-B881-E9F03B76AF49

Q36993507-21E2E3BA-4E82-4174-BC50-546F84FE25BC

Q36993507-2679C528-9160-4EE3-BCE2-56FF8CD10FC7

Q36993507-2C40AA57-E418-4F6B-81CB-9428F8E8023A

Q36993507-35A4072F-F9D4-4FFE-BDFC-CDF7ED668D31

Q36993507-3C80D069-FD0B-41B0-A205-CA49404447F2

Q36993507-3CB210F2-9CBF-4708-8D7E-5A957ED09A9C

Q36993507-4A33684D-19E2-4DDE-AAB8-8A65BD5A3449

Q36993507-58913D36-B777-4AD8-A0C5-E1A47E1FE47A

Q36993507-58A82B30-7AC6-4FD5-A532-7F10626BE9DE

P2888

Q36993507-1E0110D5-2E04-4CBC-8147-4FD9862BA4FF

P304

Q36993507-99E2CD13-8580-4AA7-B988-01822DB07422

P31

Q36993507-355BBA82-002C-406D-9C9F-BA1804031E58

P356

Q36993507-0D53FAA8-8240-4C29-B92D-698E0FB8AACC

P433

Q36993507-A07565A5-D97C-4982-A123-DB6641F66845

P478

Q36993507-399853DF-2C82-426F-8F70-FF60180A83D4

P577

Q36993507-65F5941F-0A10-44CC-8635-7F3F7CCD2663

P5875

Q36993507-2C9F5F73-10CC-4FD8-8262-FE37085ED33B

P698

Q36993507-DBF8B330-804F-4FDE-976B-23094B15DB89

P932

Q36993507-287A16D2-4E0E-47CB-9477-0F34833719B2

P356

S00415-013-6903-5

P1433

Journal of Neurology

P1476

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.

@en

P2093

Douglas L Arnold

http://www.w3.org/2001/XMLSchema#string

Samson Antel

http://www.w3.org/2001/XMLSchema#string

Sridar Narayanan

http://www.w3.org/2001/XMLSchema#string

P2860

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

Volume correction for edema in single-volume proton MR spectroscopy of contrast-enhancing multiple sclerosis lesions.

1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review.

Multiple sclerosis: is there neurodegeneration independent from inflammation?

Estimation of metabolite T1 relaxation times using tissue specific analysis, signal averaging and bootstrapping from magnetic resonance spectroscopic imaging data.

Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability.

Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease.

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS

Pathogenesis of axonal and neuronal damage in multiple sclerosis.

P2888

s00415-013-6903-5

P304

1901-1906

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00415-013-6903-5

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

260

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236185770

http://www.w3.org/2001/XMLSchema#string

P698

23589190

http://www.w3.org/2001/XMLSchema#string

P932

3705142

http://www.w3.org/2001/XMLSchema#string